Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Mirikizumab

First Posted Date: 2019-07-02

Last Posted Date: 2024-03-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT04004611

Locations: 🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
Riley Hospital for Children, Carmel, Indiana, United States

and more 34 locations

A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tirzepatide
Device: Auto-injector (AI)
Device: Prefilled syringe (PFS)

First Posted Date: 2019-07-02

Last Posted Date: 2023-04-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 47

Registration Number: NCT04004988

Locations: 🇸🇬
Lilly Nus Centre for Clin Pharmacology, Singapore, Singapore

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Conditions: Soft Tissue Sarcoma

First Posted Date: 2019-06-21

Last Posted Date: 2024-12-16

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03994627

Locations: 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸
Ironwood Cancer & Research Centers, Glendale, Arizona, United States

and more 84 locations

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Phase 4

Withdrawn

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abemaciclib
Drug: Nonsteroidal Aromatase Inhibitor (NSAI)

First Posted Date: 2019-06-17

Last Posted Date: 2019-09-06

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03988114

Locations: 🇺🇸
BayCare Medical Group, Clearwater, Florida, United States
🇺🇸
Texas Oncology-Arlington South, Arlington, Texas, United States
🇺🇸
California Cancer Associates Research and Excellence (cCARE), Fresno, California, United States

and more 112 locations

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide
Drug: Semaglutide

First Posted Date: 2019-06-17

Last Posted Date: 2022-02-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1879

Registration Number: NCT03987919

Locations: 🇺🇸
PharmQuest, Greensboro, North Carolina, United States
🇺🇸
Aventiv Research Inc, Columbus, Ohio, United States
🇺🇸
Biopharma Informatic, Inc., Houston, Texas, United States

and more 117 locations

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: Lasmiditan

First Posted Date: 2019-06-17

Last Posted Date: 2020-09-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 18

Registration Number: NCT03988088

Locations: 🇯🇵
Clinical Research Hospital, Tokyo, Shinjuku-Ku, Tokyo, Japan
🇺🇸
Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 7 locations

A Study of LY3526318 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: LY3526318
Drug: Placebo

First Posted Date: 2019-06-06

Last Posted Date: 2020-04-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 76

Registration Number: NCT03977974

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: Placebo
Drug: Galcanezumab

First Posted Date: 2019-05-24

Last Posted Date: 2023-03-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 520

Registration Number: NCT03963232

Locations: 🇨🇳
First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India

and more 37 locations

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Lasmiditan
Drug: Placebo

First Posted Date: 2019-05-24

Last Posted Date: 2021-06-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 846

Registration Number: NCT03962738

Locations: 🇯🇵
Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
🇯🇵
Tominaga Hospital, Osaka, Japan
🇯🇵
Kohnan Hospital, Kobe, Hyogo, Japan

and more 31 locations

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: LY3295668 Erbumine
Drug: Endocrine therapy
Drug: Midazolam

First Posted Date: 2019-05-20

Last Posted Date: 2020-06-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 5

Registration Number: NCT03955939

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy